Divis Laboratories Q2 results: Profit and EBITDA jump over 45% beating Street estimates

Pharmaceutical major Divi’s Laboratories reported its results for the July to September 2024 quarter in which it beat CNBC-TV18 poll estimates across parameters

Leave a Reply

Your email address will not be published. Required fields are marked *